Taking into account the well-known prognostic value of MYCN amplification, the only genetic marker retained in clinical protocols in Europe at present, pertinent genomic stratification is especially needed in MYCN non amplified low stage and infant tumours. The gene discussed is MYCN; the disease is neoplasm.